Dr Gavin Barlow is a Consultant in Infection, Hull University Teaching Hospitals NHS Tryst, and Honorary Senior Clinical Lecturer, Hull York Medical School.
Gavin qualified in Medicine at LeicesterUniversity in 1993 and trained in infectious diseases and general internal medicine in Leeds, Sheffield and Dundee, including a two-year research training fellowship at the University of Dundee. Gavin’s main clinical interests are orthopaedic infection, outpatient parenteral antibiotic therapy (OPAT), and the management of complex bacterial and healthcare-associated infections.
Gavin was awarded Fellowship of the Royal College of Physicians, London in 2009, is an Associate Editor for BMC Infectious Diseases, and is an active member of the British Society for Antimicrobial Chemotherapy (BSAC).
Research interests are broad, but predominantly focus on the epidemiology and clinical care of severe infections, common in the NHS. Gavin was recently involved in a systematic review of the cost-effectiveness of interventions to prevent healthcare associated infection in collaboration with Dawn Craig and colleagues at CRD, University of York. A previous trainee received an investigators prize at the European Congress of Clinical Microbiology & Infectious Diseases 2011 for his local work on pneumococcal disease and pneumonia, which showed the association between deprivation and incidence and that mortality increased after discharge. The latter is currently being investigated by an NIHR academic clinical fellow, work that may be important for identifying risk reduction strategies. We also recently identified high, and risk factors for, long-term mortality following bacteraemia, the lack of utility of Staph. aureus antibody tests (now rarely used) and the limitations of CURB-65. At the Federation of Infection Societies 2013, we presented 6 posters including novel clinical data on managing complex, resistant urine infections, the association between Strep. pneumoniae serotype and mortality, and our nurse-led Linezolid service.
1. Staphylococcus aureus bloodstream infection: a pooled analysis of five prospective, observational studies. Kaasch AJ, Barlow G, et al. Journal of Infection. 2013 Nov 15. doi:pii: S0163-4453(13)00335-6. 10.1016/j.jinf.2013.10.015
2. Long Term Mortality Following Blood Stream Infection. Lillie P, Allen J, Hall C, Walsh C, Adams K, Thaker H, Moss P, Barlow G. Clinical Microbiology Infection 2012 Nov 15. doi: 10.1111/1469-0691.12101
3. Increasing incidence of invasive pneumococcal disease and pneumonia despite improved vaccination uptake in Hull and East Yorkshire, United Kingdom, 2002-2009. J Elston, A Santaniello-Newton, J Meigh, D Harmer, V Allgar, T Allison, G Richardson, R Meigh, SR Palmer, G Barlow. Epidemiology and Infection 2012 Jul;140(7):1252-66.5.
4. Adjunctive Rifampicin to Reduce Early mortality from Staphylococcus aureus bacteraemia (ARREST): study protocol for a multi-centre, randomised, blinded, placebo controlled trial. Thwaites GE, Auckland C, Barlow G, et al. Trials 2012 Dec 18;13:241. doi: 10.1186/1745-6215-13-241.
5. Antibiotic prophylaxis. Hall C, Allen J, Barlow G. Surgery 2012 Dec; 30:651-658.
6. Diagnostic and prognostic markers of sepsis in critical care. Kibe S, Adams K, Barlow G. Journal of Antimicrobial Chemotherapy 2011;66 Suppl 2:ii33-40.
7. Predicting mortality in patients with community-acquired pneumonia and low CURB-65 scores. Ronan D, Nathwani D, Davey P, Barlow G. European Journal of Clinical Microbiology and Infectious Diseases 2010; 29: 1117-24. Epub 2010 Jun 3.
8. An evaluation of the usefulness of Staphylococcus aureus serodiagnosis in clinical practice. Elston J, Ling M, Jeffs B, Adams K, Thaker H, Moss P, Meigh R, Barlow G. European Journal of Clinical Microbiology and Infectious Diseases 2010; 29: 737-9. Epub 2010 Mar 19.
9. Breakthrough bacteraemia with a susceptible Enterococcus faecalis during tigecycline monotherapy. Parsonage M, Shah S, Moss P, Thaker H, Meigh R, Balaji A, Elston J, Barlow G. Journal of Antimicrobial Chemotherapy 2010 Feb;65(2):370-4.
10. Fever as nature’s engine. Some clinical data. Barlow G, Lillie P, Nathwani D, Davey P. British Medical Journal 2010 Feb 16;340:c905. doi: 10.1136/bmj.c905.
11. Evaluation of the performance of CURB65 with increasing age. Parsonage M, Nathwani D, Davey P, Barlow G. Clinical Microbiology and Infection 2009; 15: 858-64.
12. Community-acquired MRSA: The East Yorkshire Experience. Elston J, Meigh J, Kearns AM, Jordan-Owers N, Newton A, Meigh RE, Barlow G. Journal of Hospital Infection 2009; 72: 307-13.
13. Swine Flu and Antibiotics. Barlow GD. Journal of Antimicrobial Chemotherapy 2009; 64: 889-94
14. Community-Associated MRSA in the United Kingdom. Elston J, Barlow G. Journal of Infection 2009 Sep; 59: 149-55.